Letters to the Editor
Automated Office Blood Pressure for Diagnosing Hypertension
Am Fam Physician. 2021 Aug ;104(2):116-117.
To the Editor: The U.S. Preventive Services Task Force (USPSTF) recommendation statement on hypertension in adults reaffirmed the benefits of screening1; however, it missed an opportunity to promote automated office blood pressure (AOBP) measurements as an easier-to-implement alternative to ambulatory blood pressure monitoring (ABPM). The guideline states that AOBP is comparable to ABPM; however, the supporting evidence review discounted the literature on AOBP by stating, “there is substantial heterogeneity and it is unclear if lack of mean mm Hg differences would result in similar diagnostic categorization and treatment decisions.”2 The most recent and largest meta-analysis found that this heterogeneity is not clinically significant.3
The Agency for Healthcare Research and Quality evidence synthesis states, “…without analysis of test accuracy outcomes (e.g., sensitivity, specificity), it is not possible to conclude whether AOBP would result in similar clinical screening and diagnostic results as ABPM or [home blood pressure monitoring].”4 This logic is flawed. If blood pressure is a continuous outcome related to cardiovascular risk, and AOBP is similar to ABPM, then it follows that the sensitivity and specificity of AOBP will be similar to that of ABPM. Mathematically, two measures cannot be so closely matched but have different sensitivities and specificities. The only difference will be for a threshold value for hypertension. For example, a person with an average systolic blood pressure of 140.2 mm Hg with one method could have a systolic blood pressure of 139.9 mm Hg with another method. However, there is no clinically significant difference in atherosclerotic cardiovascular disease risk between these two measurements. Multiple studies now recommend treating patients based on atherosclerotic cardiovascular disease risk5; therefore, the USPSTF should acknowledge the close correlation of AOBP and ABPM and recommend using the former.
Practicality also needs to be considered. It is logistically challenging to have patients submit multiple home blood pressure readings to diagnose hypertension. It is easier to implement a screening program with AOBP machines in the outpatient setting. Each clinic needs to purchase a device and screen each patient at the desired interval. If the USPSTF wants to optimize the detection of elevated blood pressure, it should recommend AOBP because it is easy to implement and closely resembles ABPM. The USPSTF cited only one randomized trial that reported improvements in clinically meaningful outcomes (i.e., hospitalization) from hypertension screening; this trial used AOBP for screening.6
Editor's Note: See related Putting Prevention into Practice: Screening for Hypertension in Adults
Author disclosure: No relevant financial affiliations.
Referencesshow all references
1. U.S. Preventive Services Task Force. Hypertension in adults: screening. Final recommendation statement. April 27, 2021. Accessed July 2, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening...
2. Guirguis-Blake JM, Evans CV, Webber EM, et al. Screening for hypertension in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(16):1657–1669.
3. Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351–362.
4. Guirguis-Blake JM, Evans CV, Webber EM, et al. Screening for hypertension in adults: a systematic evidence review for the U.S. Preventive Services Task Force. (Prepared by Kaiser Permanente Research Affiliates Evidence-based Practice Center under contract no. HHSA-290-2015-000017-I-EPC5.) AHRQ publication no. 20-05265-EF-1. Agency for Healthcare Research and Quality; June 2020. Accessed July 2, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/hypertension-in-adults-screening
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis [published correction appears in Lancet. 2021;397(10288):1884]. Lancet. 2021;397(10285):1625–1636.
6. Kaczorowski J, Chambers LW, Dolovich L, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). BMJ. 2011;342:d442.
Send letters to email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2021 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions